Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1008 | 1009 | 1026 | 1020 | 1211 | 1293 |
Fund Return | 0.85% | 0.92% | 2.58% | 0.66% | 3.9% | 2.6% |
Place in category | 1756 | 1813 | 1657 | 1261 | 1189 | 595 |
% in Category | 82 | 86 | 85 | 69 | 80 | 64 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Robeco BP US Premium Equities I $ | 5.2B | 4.06 | 10.16 | 9.34 | ||
Robeco BP US Premium Equities K $ | 5.2B | 4.06 | 10.16 | 9.34 | ||
Robeco BP US Premium Equities F $ | 5.2B | 2.47 | 5.91 | 8.96 | ||
LU0226953718 | 5.2B | -1.43 | 12.22 | 7.39 | ||
R BP Global Premium Equities Du | 4.54B | 2.03 | 7.87 | 6.48 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
MFSM European Value Fund A1 USD | 2.69B | -1.29 | 1.47 | 4.99 | ||
MFSM European Value Fund I1 USD | 2.69B | -1.14 | 2.48 | 6.03 | ||
MFSM European Value Fund N1 USD | 2.69B | -1.35 | 0.97 | 4.46 | ||
MFSM European Value Fund W1 USD | 2.69B | -1.16 | 2.23 | 5.78 | ||
Europe Equity Plus Fund A perf acc | 1.96B | 9.06 | 6.71 | 4.68 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 3.82 | 921.8 | -0.75% | |
TotalEnergies SE | FR0000120271 | 2.99 | 66.39 | +0.61% | |
Novartis | CH0012005267 | 2.98 | 91.91 | +0.19% | |
Zurich Insurance Group | CH0011075394 | 2.97 | 469.80 | -0.04% | |
Shell | GB00BP6MXD84 | 2.96 | 32.87 | +0.52% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review